David Siegel, MD, PhD, is a Professor of Medicine at NYU Medical Center and the Division Chief of Myeloma at John Theurer Cancer Center, part of Hackensack University Medical Center, Hackensack, NJ. His medical training commenced at the NYU School of Medicine before he completed his internal medicine residency training at Bellevue Hospital Center and a hematology and medical oncology fellowship at Memorial Sloan Kettering Cancer Center. His previous roles included attending physician at the University of Arkansas for Medical Sciences and Director of stem cell transplant at Atlantic Health.
Dr Siegel is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Society for Transplantation and Cellular Therapy. He is a universally recognized leader in myeloma and has published over 400 articles in many leading medical journals.
Speaking on trialing novel therapies for myeloma and amyloidosis
Dr Siegel’s research has focused on myeloma and light chain amyloidosis, with the goal of pioneering novel therapies for patients. As a top distinguished authority in myeloma research, he has been involved in many clinical trials, including acting as chief investigator in trials of several medications that have become standard of care treatment options in myeloma. He was the lead investigator in the Phase IIb carfilzomib trial that lead to its fast-tracked approval for relapsed myeloma.